A pilot study of the effect of gemfibrozil on some haematological parameters

O’Brien, J.R.; Etherington, M. D.; Shuttleworth, R. D.; Adams, Christopher M.; Middleton, John; Goodland, F C

doi:10.1016/0049-3848(82)90292-4

Cited by 13 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact a reduction of blood fibrinogen and of plasma viscosity together with an increase of euglobulin fibrinolytic activity and of tissue plasminogen activator activity have been shown in some studies (2L, 22), while O'Brien et al (23) did not observe significant changes in fibrinogen concentration and, in accord with our observations, Schwartzkopff et al (24), Stringer et al (25) and Wilkes et al . (26) reported an increase of fibrinogen level during gemfibrozil therapy.…”

Section: +3 60+3 60+3supporting

confidence: 92%

Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

Branchi¹,

Rovellini²,

Sommariva

et al. 1993

Thromb Haemost

121

View full text Add to dashboard Cite

SummaryIn order to evaluate the effects of hypocholesterolemic drugs on plasma fibrinogen concentration, six groups of subjects with primary hypercholesterolemia have been put on treatment with diet alone or diet plus fenofibrate (100 mg t.i.d.), slow release bezafibrate (400 mg once a day), gemfibrozil (600 mg b.i.d.), simvastatin (20 mg once a day) or pravastatin (20 mg once a day) respectively. After 1 month of therapy, plasma fibrinogen significantly decreased by 9% and 15% in fenofibrate and bezafibrate groups respectively and increased by 19% in gemfibrozil treated patients. After 4 months of therapy the changes were −16% with fenofibrate, −10% with bezafibrate and +20% with gemfibrozil. No significant changes were observed in patients treated with diet alone, simvastatin or pravastatin. The fibrinogen lowering effect of fenofibrate and bezafibrate does not seem to be related to the hypolipidemic activity of the drugs.

show abstract

Section: +3 60+3 60+3supporting

confidence: 92%

Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

Branchi¹,

Rovellini²,

Sommariva

et al. 1993

Thromb Haemost

121

View full text Add to dashboard Cite

show abstract

“…In addition to the direct effect on the lipid metabolism, fibrates may exert other nonlipidic effects [ 10, 11] that play an important role in preventing the development of arterial disease. However, a platelet pro‐activating effect induced by the fibrate was reported [ 12–14].…”

Section: Introductionmentioning

confidence: 99%

Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia

Royo

Alfón

Berrozpe

et al. 2000

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…These discrepancies may either derive from differences in study group, study design or from differences in the assays employed. Studies involving gemfibrozil, for example, were performed in hyperlipidaemic patient $oups as different as hypertriglyceridaemic and/or hypercholesterolaemic patients (7, l2), survivors of myocardial infarction (9), patients with a history of tluombosis (10) and patients with severe atherosclerosis (14). The duration of these studies varied from several weeks to several months (7, 8, l2).…”

mentioning

confidence: 99%

Effects of Gemfibrozil and Ciprofibrate on Plasma Levels of Tissue-type Plasminogen Activator, Plasminogen Activator Inhibitor-1 and Fibrinogen in Hyperlipidaemic Patients

Kockx¹,

Maat²,

Knipscheer

et al. 1997

Thromb Haemost

View full text Add to dashboard Cite

SummaryEvaluation of fibrate treatment in humans has focused primarily on its anti-lipidaemic effects. A potentially favourable haemostasis-modulating activity of fibrates has also been recognized but the data are not consistent. We sought to learn more about this variability by examining the effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1) and fibrinogen in primary hyperlipidaemic patients after six and twelve weeks of treatment using different assay systems for PAI-1 and fibrinogen. Although both fibrates effectively lowered triglyceride and cholesterol levels, no effect on the elevated baseline antigen levels of t-PA and PAI-1 was observed after fibrate treatment. However, both fibrates influenced plasma fibrinogen levels, albeit in a different way. Fibrinogen antigen levels were elevated by 17.6% (p <0.05) and 24.3% (p <0.001) with gemfibrozil after six and twelve weeks, respectively, whereas with ciprofibrate there was no effect. Using a Clauss functional assay with either a mechanical end point or a turbidity-based end point, no significant change in fibrinogen levels was seen after six weeks of gemfibrozil treatment. However, after twelve weeks, gemfibrozil enhanced functional fibrinogen levels by 7.2% (p <0.05) as assessed by the Clauss mechanical assay, but decreased functional fibrinogen levels by 12.5% (p <0.0001) when a Clauss assay based on turbidity was used. After six or twelve weeks of ciprofibrate treatment, functional fibrinogen levels were decreased by 10.1% (p <0.001) and 10.5% (p <0.0001), respectively on the basis of Clauss mechanical and by 14.2% (p <0.001) and 28.2% (p <0.0001), respectively with the Clauss turbidimetric assay. A remarkable and consistent finding with both fibrates was the decrease in functionality of fibrinogen as assessed by the ratio of functional fibrinogen (determined by either of the two Clauss assays) to fibrinogen antigen.Taken together, our results indicate that at least part of the variability in the effects of fibrates on haemostatic parameters can be explained by intrinsic differences between various fibrates, by differences in treatment period and/or by the different outcomes of various assay systems. Interestingly, the two fibrates tested both reduced the functionality of fibrinogen.

show abstract

A pilot study of the effect of gemfibrozil on some haematological parameters

Cited by 13 publications

References 3 publications

Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia

Effects of Gemfibrozil and Ciprofibrate on Plasma Levels of Tissue-type Plasminogen Activator, Plasminogen Activator Inhibitor-1 and Fibrinogen in Hyperlipidaemic Patients

Contact Info

Product

Resources

About